Priyanka Bansal

Priyanka Bansal

Auto-generated profile, based on publicly available information

Priyanka Bansal

Noida Institute of Engineering and Technology (Pharmacy Institute), Knowledge Park-II, Greater Noida, Uttar Pradesh, 201306, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Recent Advances in Inflammation & Allergy Drug Discovery
Verified
Journal Article
Closed access
PDF file
AKAbhash Kumar
Abhash Kumar
AMAVIJIT MAZUMDER
AVIJIT MAZUMDER
PBPriyanka Bansal
Priyanka Bansal
Pankaj Kumar TyagiPankaj Kumar Tyagi
Pankaj Kumar Tyagi
AKAmrinder Kaur
Amrinder Kaur
This extensive analysis explores the dynamic interface between precision medicine and diabetes mellitus treatment, with a specific emphasis on wound healing in diabetic populations. Beginning with an insightful introduction, the article underscores the critical importance of effective wound healing within the broader context of diabetes mellitus, while tracing the evolutionary trajectory of precision medicine in healthcare. By elucidating the pathophysiological intricacies of diabetic wound healing, the review unveils the complex molecular mechanisms that drive this multifaceted process. Subsequently, a meticulous exploration follows into the application of precision medicine paradigms in diabetic wound care, delineating fundamental principles and diverse avenues through which precision medicine strategies can optimize diabetes management. Through a nuanced discussion of targeted therapies and interventions, the review highlights burgeoning approaches tailored to individual patient needs, accentuating the transformative potential of precision medicine in reshaping treatment paradigms. Drawing upon clinical trials and compelling case studies, the article offers valuable insights into the real-world efficacy of precision treatment modalities, elucidating successful applications and their profound implications for diabetic wound healing outcomes. Moreover, the review anticipates and addresses emerging challenges and future trajectories within the field, including the pivotal roles of biomarkers and diagnostic modalities, the integration of telemedicine platforms, and the increasing influence of artificial intelligence on diabetic wound healing endeavours. By synthesizing contemporary knowledge and delineating prospective pathways, this review underscores the catalytic potential of precision medicine in heralding a new era of enhanced outcomes for diabetic patients grappling with impaired wound healing.

8 August 2024 in The Natural Products Journal
Verified
Journal Article
Closed access
SUSanskriti Upadhyay
Sanskriti Upadhyay
AMAVIJIT MAZUMDER
AVIJIT MAZUMDER
BPBhavani Pentela
Bhavani Pentela
PBPriyanka Bansal
Priyanka Bansal
NANeeraj Agarwal
Neeraj Agarwal
DBDileep Singh Baghel
Dileep Singh Baghel
: Diabetes Mellitus (DM) is a long-term metabolic condition that has significant social, health, and economic consequences. There are various forms of diabetes mellitus, but the two most common varieties are type I and type II. Insulin-dependent diabetes (IDDM) is one of the most wellknown autoimmune illnesses that cause insulin insufficiency and hyperglycemia by either damaging or destroying Langerhans' beta cells. Available scientific data evidenced the greatest genetic contribution of Human Leukocyte Antigen class II in the IDDM. Hyperglycemia and individual components of the insulin resistance (metabolic) syndrome put people with type II diabetes at increased risk for microvascular consequences (retinopathy, nephropathy, and neuropathy) as well as macrovascular issues (cardiovascular comorbidities). A number of pathophysiological abnormalities, including obesity, poor diet, and physical inactivity, as well as genetic variables, are involved in the disturbed glucose homeostasis associated with type II diabetes. Diseases like lipid abnormalities contribute to the progression of diabetes, whereas obesity and its related medical disorders (such as hypertension, diabetes, insulin resistance, and sleep apnea syndrome) are eventually linked to an elevated cardiovascular risk. Diabetes raises the incidence, intensity, and duration of peri-densities in people with diabetes compared to healthy persons, making it a risk factor for periodontal disease. Diabetes conditions in patients concurrently also increase the progression or risk of other diseases, i.e., cardiovascular- related diseases (hypertension, oxidative stress, hyperlipidemia), nervous system-related diseases, and COVID-19, by increasing the overall infection rate. There is widespread evidence that correlates the direct connection between diabetes and other diseases, including immunity disorders, CVS disorders, etc. This review provides a correlation between diabetes and another disease with an overall impact on the progression of cardiovascular diseases, neurological diseases, COVID-19, and periodontal diseases. This current review focuses on the collation of some plants that show antidiabetic activity, including plant part, family, chemical constituent, mechanism of action, and chemical used for extraction. Studies on the role, causes, clinical management, prevention, and treatment of diabetes heavily rely on epidemiological evidence. This review also explains different factors responsible for diabetes, like genetic factors, environmental factors, and viral infections.

1 December 2025 in Current Drug Metabolism
Verified
Journal Article
Closed access
ABAnnu Bhati
Annu Bhati
AMAVIJIT MAZUMDER
AVIJIT MAZUMDER
PBPriyanka Bansal
Priyanka Bansal
SSSalahuddin Salahuddin
Salahuddin Salahuddin
Drug-induced hepatotoxicity (DIH) poses a significant clinical challenge due to its unpredictable nature and diverse manifestations. The liver, with its central role in metabolism and close association with the gastrointestinal tract, is particularly susceptible to drug-induced toxicity. DIH encompasses a spectrum of liver injuries, including hepatocellular, cholestatic, and mixed patterns, which may increase the risk of other liver diseases. This review examines diverse examples and molecular mechanisms underlying DIH, highlighting the influence of genetic predisposition, drug interactions, and pre-existing liver conditions. Given the complexity and variability of hepatotoxic responses to numerous medications, understanding these mechanisms is crucial for improving the diagnosis and management of DIH.

23 October 2025 in Current Nanomedicine
Verified
Journal Article
Closed access
PDF file
HNHari Niwas
Hari Niwas
PBPriyanka Bansal
Priyanka Bansal
BPBhavani Pentela
Bhavani Pentela
AMAVIJIT MAZUMDER
AVIJIT MAZUMDER
Background: Buchanania lanzan (Chironji), a medicinal species of the Anacardiaceae family, exhibits antioxidant, anti-inflammatory, and antimicrobial activities. Its clinical use is lim-ited due to low solubility, stability, and bioavailability. Objective: To review the phytochemical profile, pharmacological activities, and nanoformulation strategies of Buchanania lanzan to enhance its therapeutic potential. Methods: A comprehensive literature search was conducted in PubMed, Scopus, and Google Scholar for publications from 2010 to 2025 using keywords including “Buchanania lanzan”, “Chironji”, “phytochemistry”, “pharmacological activity” and, “nanoformulation.” Only peer-reviewed articles in English directly pertaining to B. lanzan were included, with emphasis on studies from the past five years. Data on plant parts, extraction methods, phytochemicals, phar-macological effects, and nanoformulations were systematically collected and categorized. Results: Buchanania lanzan contains multiple bioactive compounds, including flavonoids, tan-nins, alkaloids, glycosides, and essential oils. Nanoformulation techniques-such as polymeric na-noparticles, liposomes, nanoemulsions, and solid lipid nanoparticles-were able to improve solu-bility, stability, absorption, and controlled release. These strategies can potentially address bioa-vailability limitations and expand the plant’s applications in pharmaceuticals, nutraceuticals, and cosmeceuticals. Conclusion: Nanotechnology offers promising solutions to optimize the medicinal benefits of Buchanania lanzan. Further research is required to establish clinical efficacy, standardize formu-lations, and enable large-scale production for broader therapeutic use.

8 September 2026 in Current Drug Discovery Technologies
Verified
Journal Article
Closed access
PDF file
HAHarshita
Harshita
SDSAUMYA DAS
SAUMYA DAS
PBPriyanka Bansal
Priyanka Bansal
Diabetic retinopathy (DR) is a condition that progressively affects the microvasculature, commonly seen in individuals with diabetes, which is a leading cause of visual impairment across the globe. Approximately one-third of people with diabetes will eventually develop DR, and it remains a public health issue because the retinal damage is irreversible if the disease continues to go undiagnosed and untreated. Although various screening methods exist, including fundus photography and optical coherence tomography (OCT), they are often limited as a result of availability and expertise required for diagnosis and management. Recent advancements in artificial intelligence (AI) are transforming DR screening and diagnosis. AI has demonstrated the potential to automate retinal image evaluation with accuracies that, in some studies, approach or exceed existing standards of care; however, reported performance varies across algorithms, datasets, and clinical settings, highlighting the need for cautious interpretation and further validation in diverse populations. Machine learning (ML) & deep learning (DL) models, particularly convolutional neural networks (CNNs), have been found to have excellent performance in identifying DR-related abnormalities, including mild, moderate, and severe DR, and diabetic macular edema, at sensitivities and specificities exceeding traditional screening. AI tools under various names, such as IDx-DR, EyeArt, and Google’s AI algorithm, are quick and price-effective tests using an AI solution for early diagnosis of DR in either developed or developing economies. In addition, AI can also support predictive analytics, risk stratification, and treatment decision-making, so that ophthalmologists can provide patients with better management options. Importantly, AI also comes with its own challenges, such as data harmonization and regulatory approval for deploying AI in clinical care. This review will focus on the existing literature on the applications of AI in diagnosing and management of DR and will outline the importance of this innovation.

28 August 2026 in Current Signal Transduction Therapy
Verified
Journal Article
Closed access
PDF file
NSNidhi Singh
Nidhi Singh
AMAVIJIT MAZUMDER
AVIJIT MAZUMDER
PBPriyanka Bansal
Priyanka Bansal
Introduction: Obesity has emerged as a major global public health concern. It is a multifactorial condition encompassing genetic, environmental, socioeconomic, and psychosocial factors. This narrative review aims to highlight the key pathophysiological processes associated with chronic low-grade inflammation (CLGI) in obesity. Methods: Data collection was performed using the PubMed, Scopus, Web of Science, and Google Scholar databases, using the search terms “chronic low-grade inflammation”, “pathophysiology of obesity,” and “metabolic syndrome” to obtain relevant articles. Results: The pathophysiological sequence underlying CLGI-associated obesity begins with adipose tissue expansion, during which hypertrophic adipocytes trigger cellular stress manifested as hypoxia and ER stress, accompanied by the release of damage-associated molecular patterns (DAMPs). This initiates a vicious cycle involving the recruitment of macrophages and their proinflammatory M1 polarization, with activation of inflammatory pathways, such as NF-κB and the NLRP3 inflammasome. These changes further contribute to the induction of systemic insulin resistance and metabolic dysregulation. Discussion: Both tissue and systemic biomarkers are valuable in identifying and monitoring CLGI-associated obesity. Treatment approaches ranging from pharmacological agents and bariatric surgery to dietary modifications, exercise, and microbiome-based therapies are relevant for managing inflammation and metabolic health. Conclusion: In conclusion, strategic immunotargeting of CLGI through context-specific interventions can serve as an innovative therapeutic strategy to treat CLGI-associated obesity and potentially mitigate the resulting comorbid metabolic burden. Future efforts should prioritize the development of multi-marker approaches within precision medicine frameworks to enable more individualized care for patients with CLGI-associated obesity.